SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Eva Perón — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEva Perón
Date of birth1919-05-07
IdentifiersMRN HR-ML025-SYN-TD; SSN (made up) 000-25-7316
Document date1951-05-18
AuthorLucía Barragán, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review two weeks after completing chemoradiation and brachytherapy. [S]

History of Present Illness

Ms. Perón returns two weeks after her last brachytherapy treatment. She completed 25 fractions of pelvic radiation and five weekly cisplatin doses without a break, then four brachytherapy treatments, finishing eight weeks after the start. The bladder infection in the third week cleared with nitrofurantoin. The diarrhea settled once radiation ended and she has not needed loperamide for two weeks; nausea stopped after the last cisplatin. She has no bleeding, only a light discharge. For the past ten days she has had about eight hot flashes a day, night sweats that wake her, and vaginal dryness. She has no ringing in the ears or numbness in her hands or feet. She is very tired but walks daily and is working mornings. She has kept seeing the social worker. [S]

ElementDetail
Treatment45 Gy in 25 fractions with five weekly cisplatin doses, then four brachytherapy fractions, in eight weeks
Side effectsDiarrhea resolved; nausea gone; no ringing or numbness; tired
New symptomsHot flashes about eight a day, night sweats, vaginal dryness
BleedingNone; light discharge
ScoresPHQ-9 7; GAD-7 6; pelvic pain 1 of 10

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; night sweats; no fever
GastrointestinalNegativeBowels back to normal; no rectal bleeding
GenitourinaryPositiveVaginal dryness and light discharge; no bleeding; no urinary symptoms
EndocrinePositiveHot flashes about eight a day
NeurologicalNegativeNo numbness, tingling, or ringing in the ears
PsychiatricNegativeTired but hopeful; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairyOne tablet by mouth once dailyOral route1951-02-09 to 1951-08-17completedS
Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a dayOne or two tablets every 6 hours when needed, no more than 6 a dayOral route1951-02-09activeS
Nitrofurantoin (monohydrate and macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for 5 daysOne capsule twice daily with food for 5 daysOral route1951-03-27 to 1951-03-31completedS
Cisplatin 40 mg/m2 (64 mg) intravenous infusion once weekly for five weeks during pelvic radiation, with hydration and antiemetic premedication in the infusion center64 mg intravenously once weekly for five dosesIntravenous route1951-03-09 to 1951-04-06completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours when needed for nausea in the days after cisplatinOne tablet every 8 hours when needed for nauseaOral route1951-03-09 to 1951-04-10completedS
Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than 8 a dayTwo capsules after the first loose stool, then one after each, no more than 8 a dayOral route1951-03-09 to 1951-05-04completedS
Estradiol 0.1 mg per day transdermal patch, one patch changed twice weeklyOne patch changed twice weeklyTopical route1951-05-18activeS
Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiolOne capsule by mouth nightlyOral route1951-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1951-05-18Body height165cmS
1951-05-18Body weight50.6kgS
1951-05-18Body mass index (BMI) [Ratio]18.6kg/m2S
1951-05-18Systolic blood pressure104mm[Hg]S
1951-05-18Diastolic blood pressure66mm[Hg]S
1951-05-18Heart rate80/minS
1951-05-18Respiratory rate14/minS
1951-05-18Body temperature36.6CelS
1951-05-18Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1951-05-18Hemoglobin [Mass/volume] in Blood11.2g/dL11.6-15 g/dLLowS
1951-05-18Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
1951-05-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1946)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1951-05-18Pain severity - 0-10 verbal numeric rating [Score] - Reported1{score}S
1951-05-18Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1951-05-18Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
1951-05-18Follitropin [Units/volume] in Serum or Plasma72m[IU]/mLTypical premenopausal follicular-phase rangeHighS
1951-05-18Estradiol (E2) [Mass/volume] in Serum or Plasma14pg/mLTypical premenopausal rangeLowS
1951-05-18Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.7-2.4 mg/dLNormalS

Physical Exam

Vital signs recorded on 1951-05-18; see the Vital Signs section. [S]

SystemFinding
GeneralThin and tired; weight 50.6 kg; blood pressure 104/66
AbdomenSoft and non-tender
SkinMild darkening of the skin in the radiation field; no breakdown
PelvicGentle speculum examination: radiation changes of the upper vagina; cervix smaller, without bleeding; no mass seen

Problems

ProblemClinical statusVerificationCodeProvenance
Bleeding after intercourse and between periods, with heavier periods, for about four months, with tiredness and a dull pelvic ache. Never had cervical screening. Speculum examination shows a friable, exophytic mass about 4 cm across on the cervix that bleeds on contact. Punch biopsy, HPV test and cytology taken; urgent gynecologic oncology consultation bookedresolvedconfirmed N93.8S — Synthetic presenting problem linked to her documented abnormal bleeding with anemia; superseded by the diagnosis at the consultation.
Iron deficiency anemia from chronic blood loss: hemoglobin 9.4 g/dL, mean cell volume 72 fL, ferritin 6 ng/mL, with tiredness and breathlessness on stairsactiveconfirmed D50.0S — Synthetic modern finding linked to her documented anemia from vaginal bleeding.
Invasive squamous cell carcinoma of the cervix, HPV 16 positive: an exophytic tumor about 4.5 cm across with clinical involvement of the left parametrium, not reaching the pelvic wall; pelvic MRI and PET-CT ordered for FIGO 1943 staging. Synthetic modern episode linked to her documented cervical canceractiveconfirmed C53.9S — Synthetic modern diagnosis made at the gynecologic oncology consultation.
Acute cystitis during pelvic chemoradiation: two days of new burning, urgency and cloudy urine on top of mild radiation frequency, without fever or flank pain; urine dipstick positive for leukocyte esterase and nitrite; culture grew Escherichia coli sensitive to nitrofurantoin; neutrophil count and kidney function normal; resolvedresolvedconfirmed N30.00S — Synthetic acute infection; not a historical claim.
Ovarian failure after pelvic radiation, with hot flashes, night sweats, poor sleep and vaginal dryness two weeks after treatment; FSH 72 mIU/mL and estradiol 14 pg/mLactiveconfirmed E89.41S — Synthetic expected effect of pelvic chemoradiation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationTreatment side effects (bowel, bladder, skin, nausea, hearing, nerve symptoms)Weekly during treatment, then at each visitCompleted todayDiarrhea and nausea resolved; skin intact; no hearing loss or neuropathy
LaboratoryKidney function (creatinine, eGFR) and magnesium for cisplatinBefore cisplatin, weekly during it, and afterCompleted todayCreatinine 0.8 mg/dL, eGFR 101, magnesium 1.9 mg/dL
LaboratoryBlood count (hemoglobin, white cells, platelets)About one month after starting oral iron, then every three months for a year; weekly during chemoradiationCompleted todayHemoglobin 11.2 g/dL
LaboratoryOvarian function (FSH, estradiol)When menopause symptoms appear after pelvic radiationCompleted todayFSH 72 mIU/mL, estradiol 14 pg/mL: ovarian failure
ExaminationPelvic, speculum and rectovaginal examinationAt diagnosis; every three to six months for two years after treatmentCompleted todayGentle speculum examination: cervix smaller; no mass seen
ImagingFDG PET-CTAt staging; about three months after chemoradiationDueAbout three months after treatment
SurveyPelvic pain score and analgesic safety (no anti-inflammatory painkillers with cisplatin)Every visitCompleted today1 of 10
SurveyPHQ-9 and GAD-7At diagnosis, before treatment, at mid-treatment, at the end of treatment, and in follow-upDeferredPHQ-9 7 and GAD-7 6 today. The mid-treatment measures were not done: the only visit here during treatment was the sick visit for cystitis, and the weekly oncology reviews did not record them. No harm resulted: scores fell from diagnosis to today, and the social worker saw her weekly. Corrective action: the social worker now records the PHQ-9 and GAD-7 at the mid-treatment review
Self-managementVaginal dilator useStarting two to four weeks after radiation, three times a weekCompleted todayTaught today; three times a week
Medication safetyHormone therapy safety (blood pressure, clot symptoms) and symptom controlAt the start and every visitCompleted todayBlood pressure 104/66; no clot history; starts today
ReferralSurvivorship care plan and gynecologic oncology follow-upFrom the end of treatmentCompleted todayGynecologic oncology every three months for two years

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027); Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update (2018); Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026)

Follow-up: Gynecologic oncology review in one month. PET-CT and review here about three months after treatment. Next scheduled visit 1951-08-17: review three months after treatment: PET-CT response, examination, anemia, mood, and the follow-up plan. [S]